Pfizer, BioNTech: COVID-19 vaccine on track for review in October

Covid-19Pfizer, BioNTech: COVID-19 vaccine on track for review in October

Date:

Pfizer, BioNTech: COVID-19 vaccine on track for review in October

U.S. drugmaker Pfizer and partner BioNTech say their COVID-19 vaccine candidate is on track for regulatory review as soon as October, if it continues to provide positive results.

The companies provided more data Thursday on what they called “positive” results from the Phase 1 study for the vaccine candidate, BNT162b2.

A pivotal Phase 2/3 global study for the potential vaccine with as many as 30,000 participants is now underway.

“BNT162b2 remains under clinical study and is not currently approved for distribution anywhere in the world. Assuming clinical success, Pfizer and BioNTech are on track to seek regulatory review for BNT162b2 as early as October 2020,” they said in a statement. “If regulatory authorization or approval is obtained, [we] currently plan to supply up to 100 million doses worldwide by the end of 2020 and approximately 1.3 billion doses by the end of 2021.”

Share post:

Subscribe

Popular

More like this
Related

Know why explore India more at the onset of 2023

India is known around the world for its rich culture,...

3 minors booked for making obscene comments on their female teacher

Meerut (UP): The police booked three minor students and...

Effective tips to improve your immunity this winter

Winter is one of the best seasons to enjoy during...

UP begins process for urban local bodies’ polls

Lucknow: Uttar Pradesh has begun the process for holding...